Tag Archives: kyprolis

October, 2018

August, 2018

June, 2018

January, 2018

  • 18 January

    FDA Approves Addition of Overall Survival Data to Kyprolis Label

    THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS® (carfilzomib). Data …

October, 2017

September, 2017

July, 2017

March, 2017

November, 2016

September, 2016

  • 27 September

    Amgen’s Kyprolis Fails Key First-Line Multiple Myeloma Trial

    THOUSAND OAKS, Calif., Sept. 27, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 CLARION trial, which evaluated an investigational regimen of KYPROLIS® (carfilzomib), melphalan and prednisone (KMP) versus Velcade® (bortezomib), melphalan and prednisone (VMP) for 54 weeks in patients with newly diagnosed multiple myeloma …